Matrix metalloproteinase-2 (MMP-2 ) and-9 (MMP-9) gene variants and microvascular complications in type 2 diabetes patients

1IDF Diabetes Atlas Ninth edition 2019. IDF Diabetes Atlas Ninth edition 2019Search in Google Scholar

2Callaghan BC, Price RS, Feldman EL. Distal Symmetric Polyneuropathy: A Review. JAMA. 2015; 314: 2172–2181. Callaghan BC Price RS Feldman EL Distal Symmetric Polyneuropathy: A Review JAMA 2015 314 2172 218110.1001/jama.2015.13611512508326599185Search in Google Scholar

3Afkarian M, et al. Clinical Manifestations of Kidney Disease among US Adults with Diabetes, 1988-2014. JAMA. 2016; 316: 602–610. Afkarian M et al Clinical Manifestations of Kidney Disease among US Adults with Diabetes, 1988-2014 JAMA 2016 316 602 61010.1001/jama.2016.10924544480927532915Search in Google Scholar

4Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015; 2-17. Lee R Wong TY Sabanayagam C Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss Eye Vis (Lond) 2015 2 1710.1186/s40662-015-0026-2465723426605370Search in Google Scholar

5Doria A. Genetics of Diabetes Complications. Curr Diab Rep. 2010; 10(6): 467–475. Doria A Genetics of Diabetes Complications Curr Diab Rep 2010 106 467 47510.1007/s11892-010-0147-x295684720835900Search in Google Scholar

6Negase H, Woessnsner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999; 274:21491-21494. Negase H Woessnsner JF Jr Matrix metalloproteinases J Biol Chem 1999 27421491 2149410.1074/jbc.274.31.2149110419448Search in Google Scholar

7Nikolaos P, Kadoglou, Daskalopoulou S, Perrera D, Liapis C. Matrix Metalloproteinases and Diabetic Vascular Complications. Angiology. 2005; 56: 173–189. Nikolaos P Kadoglou Daskalopoulou S Perrera D Liapis C Matrix Metalloproteinases and Diabetic Vascular Complications Angiology 2005 56 173 18910.1177/00033197050560020815793607Search in Google Scholar

8Kowluru RA, Mishra M. Regulation of Matrix Metalloproteinase in the Pathogenesis of Diabetic Retinopathy. Prog Mol Biol Transl Sci. 2017; 148: 67-85. Kowluru RA Mishra M Regulation of Matrix Metalloproteinase in the Pathogenesis of Diabetic Retinopathy Prog Mol Biol Transl Sci 2017 148 67 8510.1016/bs.pmbts.2017.02.00428662829Search in Google Scholar

9Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med Overseas Ed. 2012; 366:1227-39. Antonetti DA Klein R Gardner TW Diabetic retinopathy N Engl J Med Overseas Ed 2012 3661227 3910.1056/NEJMra100507322455417Search in Google Scholar

10Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35: 556–564. Yau JW Rogers SL Kawasaki R et al Global prevalence and major risk factors of diabetic retinopathy Diabetes Care 2012 35 556 56410.2337/dc11-1909332272122301125Search in Google Scholar

11Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010; 376: 124–36. Cheung N Mitchell P Wong TY Diabetic retinopathy Lancet 2010 376 124 3610.1016/S0140-6736(09)62124-320580421Search in Google Scholar

12Diabetes Control and Complications Trial Research Group.The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995; 44: 968–983. Diabetes Control and Complications Trial Research Group The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial Diabetes 1995 44 968 98310.2337/diab.44.8.968Search in Google Scholar

13Jerneld B, Algvere P. Relationship of duration and onset of diabetes to prevalence of diabetic r.tinopathy. Am. J. Ophtalmol. 1986; 102: 431–437. Jerneld B Algvere P Relationship of duration and onset of diabetes to prevalence of diabetic r.tinopathy Am. J. Ophtalmol 1986 102 431 43710.1016/0002-9394(86)90069-33766657Search in Google Scholar

14Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus UKPDS 69. Arch. Ophthalmol. 2004; 122(11): 1631–1640. Matthews DR Stratton IM Aldington SJ Holman RR Kohner EM Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus UKPDS 69 Arch. Ophthalmol 2004 12211 1631 164010.1001/archopht.122.11.163115534123Search in Google Scholar

15Simó-Servat O, Hernández O, Simó R. Genetics in diabetic retinopathy: Current Concepts and New Insights. Curr Genomics. 2013; 14(5): 289–299. Simó-Servat O Hernández O Simó R Genetics in diabetic retinopathy: Current Concepts and New Insights Curr Genomics 2013 145 289 29910.2174/13892029113149990008376368024403848Search in Google Scholar

16Giebel S, Menicucci G, Mc Guire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of blood – retinal barrier. Lab Invest. 2005; 85: 567-607. Giebel S Menicucci G Mc Guire PG Das A Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of blood – retinal barrier Lab Invest 2005 85 567 60710.1038/labinvest.370025115711567Search in Google Scholar

17Mohammad G, Kowluru RA. Matrix metalloproteinase -2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab Invest. 2010; 90(9): 1365-1372. Mohammad G Kowluru RA Matrix metalloproteinase -2 in the development of diabetic retinopathy and mitochondrial dysfunction Lab Invest 2010 909 1365 137210.1038/labinvest.2010.89292506320479714Search in Google Scholar

18Grant MB, Caballero S, Tarnuyyer RW, Bass KE, Ljubinkov AV, Spoerri PE, Galardy RE. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes. 1998; 47: 1311-7. Grant MB Caballero S Tarnuyyer RW Bass KE Ljubinkov AV Spoerri PE Galardy RE Matrix metalloproteinase expression in human retinal microvascular cells Diabetes 1998 47 1311 710.2337/diab.47.8.13119703333Search in Google Scholar

19Salzmann J, Limb GA, Khaw PT, Gregor Z, Webster L, Chignell AH, Charteris D. Matrix metalloproteinase and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophtalmo. 2000; 84: 1091-6. Salzmann J Limb GA Khaw PT Gregor Z Webster L Chignell AH Charteris D Matrix metalloproteinase and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy Br J Ophtalmo 2000 84 1091 610.1136/bjo.84.10.1091172327511004090Search in Google Scholar

20Singh K, Goyal P, Singh M, Deshmukh S, Upadhyay D, Kant S, Agrawal NK, Gupta SK, Singh K. Association of functional SNP-1562C>T in MMP-9 promoter with proliferative diabetic retinopathy in north Indian type 2 diabetes mellitus patients. J Diabetes Complications. 2017; 31(12): 1648-1651. Singh K Goyal P Singh M Deshmukh S Upadhyay D Kant S Agrawal NK Gupta SK Singh K Association of functional SNP-1562C>T in MMP-9 promoter with proliferative diabetic retinopathy in north Indian type 2 diabetes mellitus patients J Diabetes Complications 2017 3112 1648 165110.1016/j.jdiacomp.2017.08.01028964682Search in Google Scholar

21Beranek M, Kolar P, Tschoplova S, Kankova K, Vasku A. Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2 ) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Molecular Visio. 2008; 14: 1114-1121. Beranek M Kolar P Tschoplova S Kankova K Vasku A Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2 ) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy Molecular Visio 2008 14 1114 1121Search in Google Scholar

22Singh R, Kishore L, Kaur N: Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res. 2014; 80: 21–35. Singh R Kishore L Kaur N Diabetic peripheral neuropathy: current perspective and future directions Pharmacol Res 2014 80 21 3510.1016/j.phrs.2013.12.00524373831Search in Google Scholar

23Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006; 81(4): S3–11. Argoff CE Cole BE Fishbain DA et al Diabetic peripheral neuropathic pain: clinical and quality-of-life issues Mayo Clin Proc 2006 814 S3 1110.1016/S0025-6196(11)61474-2Search in Google Scholar

24Jann S, Bramerio MA, Beretta S, Koch S, Defanti CA, et al. Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIPD. Neurology. 2003; 61: 1607-1610. Jann S Bramerio MA Beretta S Koch S Defanti CA et al Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIPD Neurology 2003 61 1607 161010.1212/01.WNL.0000096174.86850.7FSearch in Google Scholar

25Kuhad A, Singh P, Chopra K. Matrix metalloproteinases: potential therapeutic target for diabetic neuropathic pain. Expert Opin Ther Targets. 2015; 19(2): 177-85. Kuhad A Singh P Chopra K Matrix metalloproteinases: potential therapeutic target for diabetic neuropathic pain Expert Opin Ther Targets 2015 192 177 8510.1517/14728222.2014.96084425243524Search in Google Scholar

26Deng X, Ma P, Wu M, Liao H, Sung XJ. Role of matrix metalloproteinases in myelin abnormalities and mechanical allodynia in rodents with diabetic neuropathy. Aging Dis. 2021; 12(7): 1808-1820. Deng X Ma P Wu M Liao H Sung XJ Role of matrix metalloproteinases in myelin abnormalities and mechanical allodynia in rodents with diabetic neuropathy Aging Dis 2021 127 1808 182010.14336/AD.2021.0126846030134631222Search in Google Scholar

27Singh K, Agrawal NK, Gupta SK, Singh K. A functional single nucleotide polymorphism -1562C>T in the matrix metalloproteinase-9 promoter is associated with type 2 diabetes and diabetic foot ulcers. Int J Low Extrem Wounds. 2013; 12(3): 199-204. Singh K Agrawal NK Gupta SK Singh K A functional single nucleotide polymorphism -1562C>T in the matrix metalloproteinase-9 promoter is associated with type 2 diabetes and diabetic foot ulcers Int J Low Extrem Wounds 2013 123 199 20410.1177/153473461349328924043671Search in Google Scholar

28Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes care. 2014; 37: 2864-2883. Tuttle KR Bakris GL Bilous RW et al Diabetic kidney disease: a report from an ADA Consensus Conference Diabetes care 2014 37 2864 288310.2337/dc14-1296417013125249672Search in Google Scholar

29United States Renal Data System. Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2016. United States Renal Data System. Annual Data Report: Epidemiology of Kidney Disease in the United States Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2016Search in Google Scholar

30Maeda S, Haeda M, Guo B, et al. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int. 2001; 60: 1428-1434. Maeda S Haeda M Guo B et al Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy Kidney Int 2001 60 1428 143410.1046/j.1523-1755.2001.00945.x11576356Search in Google Scholar

31Shalaby, K., Bahriz, R., Mahsoub, N. et al. Matrix metalloproteinase-9 gene polymorphism (-1562 C/T) and its correlation with diabetic nephropathy. Egypt J Intern Med. 2021; 33: 7. Shalaby K. Bahriz R. Mahsoub N. et al Matrix metalloproteinase-9 gene polymorphism (-1562 C/T) and its correlation with diabetic nephropathy Egypt J Intern Med 2021 33 710.1186/s43162-021-00035-2Search in Google Scholar

32Feng S, Ye G, Bai S, Wei H, Liao X, Li L. Matrix Metalloproteinase-9 -1562C/T Gene Polymorphism Is Associated with Diabetic Nephropathy. Biomed Res Int. 2016; 1627143. Feng S Ye G Bai S Wei H Liao X Li L Matrix Metalloproteinase-9 -1562C/T Gene Polymorphism Is Associated with Diabetic Nephropathy Biomed Res Int 2016 162714310.1155/2016/1627143500731527631001Search in Google Scholar

33Gantala SR, Kondapalli MS, Kummari R, Padala C, Tupurani MA, et al. Collagenase-1 (-1607 1G/2G), Gelatinase-A (-1306 C/T), Stromelysin-1 (-1171 5A/6A) functional promoter polymorphisms in risk prediction of type 2 diabetic nephropathy. Gene. 2018; 673: 22-31. Gantala SR Kondapalli MS Kummari R Padala C Tupurani MA et al Collagenase-1 (-1607 1G/2G), Gelatinase-A (-1306 C/T), Stromelysin-1 (-1171 5A/6A) functional promoter polymorphisms in risk prediction of type 2 diabetic nephropathy Gene 2018 673 22 3110.1016/j.gene.2018.06.00729883760Search in Google Scholar

34Behrforouz A, Dastgheib SA, Abbasi H, Karimi-Zarrchi M, Javaheri A, Hadadan A, Tabatabaei RS, Meibodi B, Neamatzadeh H. Association of MMP-2, MMP-3 and MMP-9 polymorhisms with susceptibility to recurrent pregnancy loss. Fetal Pediatr Pathol. 2021; 40(5): 378-386. Behrforouz A Dastgheib SA Abbasi H Karimi-Zarrchi M Javaheri A Hadadan A Tabatabaei RS Meibodi B Neamatzadeh H Association of MMP-2, MMP-3 and MMP-9 polymorhisms with susceptibility to recurrent pregnancy loss Fetal Pediatr Pathol 2021 405 378 38610.1080/15513815.2019.171087931955640Search in Google Scholar

35Sarray S, Dallel M, Lamine LBj Jairajpuri D, Sellami N et al. Association of matrix metalloproteinase-2 gene polymorphism with susceptibility to type 2 diabetesː A case control study. J Diabetes Complications. 2021; 35(6): 107908. Sarray S Dallel M Lamine LBj Jairajpuri D Sellami N et al Association of matrix metalloproteinase-2 gene polymorphism with susceptibility to type 2 diabetesː A case control study J Diabetes Complications 2021 356 10790810.1016/j.jdiacomp.2021.10790833766491Search in Google Scholar